Neurocrine Biosciences Reports Q2 2026 Financial Results

What Happened
Neurocrine Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2026, via a press release dated July 30, 2026. The company furnished the press release as Exhibit 99.1 to Form 8‑K under Item 2.02 (Results of Operations and Financial Condition). The Form 8‑K was signed by Matthew C. Abernethy, Chief Financial Officer, on July 30, 2026.

Key Details

• Event: Quarterly results announced for the three months ended June 30, 2026 (Q2 2026).
• Filing: Form 8‑K filed July 30, 2026; press release attached as Exhibit 99.1.
• Disclosure note: Per General Instruction B.2 to Form 8‑K, the furnished information (including Exhibit 99.1) is not “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings.
• Signature: Report signed by Matthew C. Abernethy, Chief Financial Officer (Principal Financial Officer).

Why It Matters
This 8‑K signals Neurocrine’s official release of its latest quarterly earnings and financial condition information — primary material for investors evaluating recent revenue, earnings, guidance, or other operational updates. Investors should read the attached press release (Exhibit 99.1) for the specific numbers and management commentary, and watch for any related investor call or subsequent filings that provide detailed financial statements or forward‑looking guidance.